We are live on
!
Find out more
Protagonist Therapeutics
PTGX
PTGX
317 hedge funds and large institutions have $8.3B invested in Protagonist Therapeutics in 2026 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 110 increasing their positions, 102 reducing their positions, and 47 closing their positions.
New
Increased
Maintained
Reduced
Closed
225% more call options, than puts
Call options by funds: $36.2M | Put options by funds: $11.1M
34% more capital invested
Capital invested by funds: $6.18B → $8.3B (+$2.12B)
26% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 47
10.28% more ownership
Funds ownership: 113.13% → 123.41% (+10%)
1% more funds holding
Funds holding: 313 → 317 (+4)
8% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 102
23% less funds holding in top 10
Funds holding in top 10: 13 → 10 (-3)
Holders
317
Holders Change
+4
Holders Change %
+1.28%
% of All Funds
3.9%
Holding in Top 10
10
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-23.08%
% of All Funds
0.12%
New
59
Increased
110
Reduced
102
Closed
47
Calls
$36.2M
Puts
$11.1M
Net Calls
+$25.1M
Net Calls Change
-$55.5M
Top Buyers
| 1 |
UBS Group
Zurich,
Switzerland
|
+$213M |
| 2 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$73.4M |
| 3 |
Jennison Associates
New York
|
+$65.6M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$52.8M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$37.9M |
Top Sellers
| 1 |
CC
Commodore Capital
New York
|
-$39.3M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$35.1M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$33.5M |
| 4 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$18M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$17.4M |
